High plasma levels of betaine, a trimethylamine N‐Oxide‐related metabolite, are associated with the severity of cirrhosis

摘要

Abstract Background and Aims The gut microbiome‐related metabolites betaine and trimethylamine N‐oxide (TMAO) affect major health issues. In cirrhosis, betaine metabolism may be diminished because of impaired hepatic betaine homocysteine methyltransferase activity, whereas TMAO generation from trimethylamine may be altered because of impaired hepatic flavin monooxygenase expression. Here, we determined plasma betaine and TMAO levels in patients with end‐stage liver disease and assessed their relationships with liver disease severity. Methods Plasma betaine and TMAO concentrations were measured by nuclear magnetic resonance spectroscopy in 129 cirrhotic patients (TransplantLines cohort study; NCT03272841) and compared with levels from 4837 participants of the PREVEND cohort study. Disease severity was assessed by Child‐Pugh‐Turcotte (CPT) classification and Model for End‐stage Liver Disease (MELD) score. Results Plasma betaine was on average 60 higher (p?